Jul 21, 2016 | News
On Wednesday, July 27th in Toronto, T3D Therapeutics will present Preliminary Results of a 36-patient, two-week Phase 2a Open Label Feasibility Clinical Trial, showing Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated...
Jun 23, 2016 | News
T3D Therapeutics has received FDA approval for an open-label, 26-week extension study in mild to moderate Alzheimer’s disease patients extending its Phase 2a feasibility study of T3D-959, an investigational new drug candidate that has the potential to be...
Jun 8, 2016 | News
T3D Therapeutics, Inc. has achieved a significant clinical trial milestone in its Phase 2a feasibility study in mild to moderate Alzheimer’s disease patients with T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing,...
Dec 7, 2015 | News
Research Triangle Park, NC, December 7, 2015 – T3D Therapeutics today announced it will present a company update at the 8th Annual Biotech Showcase conference in San Francisco. The presentation is at the Parc 55 San Francisco, a Hilton hotel on Jan.13, 2016, at 11:15...
Dec 7, 2015 | News
Research Triangle Park, NC, December 7, 2015 – T3D Therapeutics today announced it will present a company update at the 1st Annual Neuroscience BioPartnering and Investment Forum conference in New York City. The presentation is at the New York Academy of Sciences on...
